サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1772409

外用薬CDMOの市場規模・シェア・動向分析レポート：剤形別、サービス別、最終用途別、地域別、セグメント予測、2025年～2033年

Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Formulation (Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products), By Service, By End-use, By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
外用薬CDMOの市場規模・シェア・動向分析レポート：剤形別、サービス別、最終用途別、地域別、セグメント予測、2025年～2033年
出版日: 2025年06月16日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

外用薬CDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の外用薬CDMO市場規模は2033年までに142億2,000万米ドルに達し、2025年から2033年までのCAGRは7.5％を記録すると予測されています。

様々な皮膚関連疾患や皮膚科疾患に対処するための特殊な外用薬に対するニーズが高まっています。ヘルスケアプロバイダーや患者はカスタマイズされたソリューションを求めており、外用薬に特化した専門知識を持つCDMOに対する需要の高まりにつながっています。

市場は断片化されており、複数の企業が同様の技術力と加工能力を有しています。マイクロエマルション、ナノテクノロジー、経皮パッチなどの革新的なドラッグデリバリー技術の開発により、CDMOの能力は、より患者にやさしく効果的な外用医薬品を開発する能力を高めています。さらに、個別化医療に向けた動向の高まりは、外用薬CDMOの需要を大幅に押し上げています。CDMOは、外用薬治療を個々の患者の状態やニーズに合わせて個別化する上で基本的な役割を果たすからです。

CDMOと製薬企業とのコラボレーションが増加し、CDMOは革新的で新しい外用薬の製造と開発に貢献しています。製薬会社は、研究、流通、マーケティングなどのコアコンピタンスに集中する一方で、製造サービスを専門のCDMOに委託する目的で、アウトソーシングを選択することが多いです。外用薬のFDA承認や製品上市の増加は、外用薬製造専門のCDMOの成長に大きく寄与しています。例えば、2022年5月、ダーマバント・サイエンシズは、成人の尋常性乾癬の局所管理用のVTAMA（タピナロフ）クリーム1％の米国食品医薬品局（FDA）の承認を取得しました。

COVID-19パンデミックは市場にマイナスの影響を与えました。パンデミックは世界のサプライチェーンを大きく混乱させ、製造能力や原材料の入手に影響を与えました。外用薬を含むいくつかの臨床試験は、安全性への懸念から一時的に延期または保留されました。このため、新しい外用薬の治療や製剤の試験・開発が妨げられました。しかし、買収や専門医薬品プロバイダーとの提携といった戦略的イニシアチブを採用することで、業界は2021年までに市場シェアを回復しました。

外用薬CDMO市場レポートハイライト

  • 剤形別では、半固形製剤分野が2024年に66.44%の最大売上シェアを占めました。同分野は、クリーム、ゲル、軟膏の需要拡大と、外用薬を含む臨床試験の増加によって牽引されています。一方、クリームのサブカテゴリーは、いくつかの病状に対する外用クリームの承認が増加しているため、大きなシェアを占めています。
  • サービス別では、受託製造セグメントが2024年に最大の売上シェアを占めました。同分野のシェアが高いのは、主に製造委託の費用対効果に後押しされ、製造委託サービスへの需要が高まっているためです。
  • 最終用途別では、外用薬の開発に関連する研究開発活動が活発化していることから、バイオ製薬企業が予測期間中に最も高いCAGRを記録すると予測されています。
  • アジア太平洋地域は予測期間中に大きなCAGRを記録すると予測されています。同地域の大幅な成長は、主にアジアのいくつかの経済圏で人件費と運用コストが低いため、外用製品のコスト効率の高い製造に起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 外用薬CDMO市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • テクノロジー情勢
  • 価格モデル分析
  • 研究開発費分析（2021～2024年）
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • SWOT分析によるPESTEL

第4章 外用薬CDMO市場：剤形別の推定・動向分析

  • 外用薬CDMO市場、剤形別：セグメントダッシュボード
  • 外用薬CDMO市場、剤形別：変動分析
  • 剤形別、2021年～2033年
  • 半固形製剤
    • クリーム
    • 軟膏
    • ゲル
    • その他
  • 液体製剤
  • 固形製剤
  • 経皮吸収型製品

第5章 外用薬CDMO市場：サービス別の推定・動向分析別指標

  • 外用薬CDMO市場、サービス別セグメントダッシュボード
  • 外用薬CDMO市場、サービス別：変動分析
  • サービス別、2021年～2033年
  • 受託開発
  • 受託製造

第6章 外用薬CDMO市場：最終用途の推定・動向分析

  • 外用薬CDMO市場、最終用途別：セグメントダッシュボード
  • 外用薬CDMO市場、最終用途別：変動分析
  • 最終用途別、2021年～2033年
  • 製薬会社
  • バイオ医薬品企業
  • その他

第7章 外用薬CDMO市場：地域別推定・動向分析

  • 地域別市場ダッシュボード
  • 地域別市場シェア分析、2024年および2033年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参入企業
  • 市況分析、2024年（ヒートマップ分析）
  • 企業プロファイル
    • Lubrizol Life Science
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited
    • Bora Pharmaceutical CDMO
    • Ascendia Pharmaceuticals
    • Pierre Fabre group
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD
    • MedPharm Ltd
    • PCI Pharma Services

第9章 主な推奨事項

図表

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 Global Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 5 Global Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6 Global Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 7 Global Topical Drugs CDMO Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • Table 8 North America Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 9 North America Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 10 North America Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 11 North America Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 12 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 13 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 14 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 15 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Canada Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 17 Canada Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 18 Canada Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 19 Mexico Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 20 Mexico Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 21 Mexico Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 22 Europe Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 23 Europe Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 24 Europe Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 25 Europe Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 26 UK Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 27 UK Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 28 UK Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 29 Germany Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 30 Germany Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 31 Germany Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 32 France Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 33 France Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 34 France Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 35 Italy Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 36 Italy Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 37 Italy Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 38 Spain Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 39 Spain Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 40 Spain Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 41 Denmark Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 42 Denmark Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 43 Denmark Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 44 Sweden Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 45 Sweden Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 46 Sweden Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 47 Norway Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 48 Norway Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 49 Norway Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 53 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 54 Japan Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 55 Japan Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 56 Japan Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 57 China Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 58 China Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 59 China Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 60 India Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 61 India Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 62 India Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 63 Australia Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 64 Australia Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 65 Australia Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 66 Thailand Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 67 Thailand Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 68 Thailand Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 69 South Korea Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 70 South Korea Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 71 South Korea Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 72 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 73 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 74 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 75 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 76 Brazil Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 77 Brazil Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 78 Brazil Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 79 Argentina Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 80 Argentina Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 81 Argentina Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 84 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 85 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 86 South Africa Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 87 South Africa Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 88 South Africa Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 90 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 91 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 92 UAE Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 93 UAE Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 94 UAE Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 96 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 97 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 Topical Drugs CDMO Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Topical Drugs CDMO Market: Formulation outlook and key takeaways
  • Fig. 20 Topical Drugs CDMO Market: Formulation movement analysis
  • Fig. 21 Semi-solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Creams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Ointments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Gel Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Liquid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Transdermal Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Topical Drugs CDMO Market: Service outlook and key takeaways
  • Fig. 30 Topical Drugs CDMO Market: Service movement analysis
  • Fig. 31 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Topical Drugs CDMO Market: End Use outlook and key takeaways
  • Fig. 34 Topical Drugs CDMO Market: End Use movement analysis
  • Fig. 35 Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Regional Marketplace: Key Takeaways
  • Fig. 39 North America Topical Drugs CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 U.S. Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Spain Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Thailand Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 South Korea Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Brazil Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Argentina Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 MEA Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 South Africa Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 UAE Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key company categorization
  • Fig. 91 Service heat map analysis
  • Fig. 92 Strategic framework
目次
Product Code: GVR-4-68040-150-0

Topical Drugs CDMO Market Growth & Trends:

The global topical drugs CDMO market size is expected to reach USD 14.22 billion by 2033, registering a CAGR of 7.5% from 2025 to 2033, according to a new report by Grand View Research, Inc. There is an increasing need for specialized topical drugs to address various skin-related and dermatological conditions. Healthcare providers and patients seek customized solutions, leading to a rise in demand for CDMOs with specialized expertise in topical drugs.

The market is fragmented, with several players having similar technological and processing capabilities. The development of innovative drug delivery technologies, such as microemulsions, nanotechnology, and transdermal patches, has extended the abilities of CDMOs to create more patient-friendly and effective topical drug products. Furthermore, a growing trend towards personalized medicine has significantly boosted demand for topical drug CDMOs, as they play a fundamental role in personalizing topical treatments to individual patient conditions and needs.

Collaborations between CDMOs and pharmaceutical companies have risen, with CDMOs contributing to the manufacturing and development of innovative and new topical drugs. Pharmaceutical firms significantly opt for outsourcing with an aim to focus on core competencies such as research, distribution, and marketing while entrusting manufacturing services to dedicated CDMOs. The increasing number of FDA approvals and product launches in topical medications significantly contributes to CDMOs specializing in topical drug manufacturing growth. For instance, in May 2022, Dermavant Sciences received the U.S. Food and Drug Administration (FDA) approval for its VTAMA (tapinarof) cream, 1%, for the topical management of plaque psoriasis in adults.

The COVID-19 pandemic negatively impacted the market. The pandemic has significantly disrupted the global supply chains, affecting the accessibility of manufacturing capabilities and raw materials. Several clinical studies, including those for topical medicine, were temporarily delayed or put on hold owing to safety concerns. This disturbed the testing and development of new topical drug treatments and formulations. However, by adopting strategic initiatives such as acquisition and partnerships with specialized drug providers, the industry regained its market shares by 2021.

Topical Drugs CDMO Market Report Highlights:

  • Based on formulation, the semi-solid formulations segment held the largest revenue share of 66.44% in 2024.The segment is driven by the growing demand for creams, gels, and ointments and the rise in clinical trials involving topical drugs. The cream sub-category, on the other hand, held the lion's share owing to increasing approval of topical creams for several medical conditions.
  • Based on the service, the contract manufacturing segment held the largest revenue share in 2024. The high shares of the segment are majorly due to the growing demand for outsourced manufacturing services, driven by the cost-effectiveness of outsourced manufacturing.
  • In terms of end-use, the biopharmaceutical companies segment is anticipated to witness highest CAGR during the forecast period owing to the rise in focus on R&D activities pertaining to the development of topical medication.
  • Asia Pacific is anticipated to register the significant CAGR over the forecast period. The region's substantial growth is primarily attributed to the cost-effective manufacturing of topical products due to lower labor and operational costs in several Asian economies.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Formulation
    • 1.2.2. Service
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Topical Drugs CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High demand for non-invasive treatment options to boost sales of topical drugs
      • 3.2.1.2. Growing pipeline of topical drugs
      • 3.2.1.3. Growing research and development investments
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. Limited efficacy in certain conditions limits adoption of topical products
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. R&D Spending Analysis (2021-2024)
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Force Analysis
    • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Topical Drugs CDMO Market: Formulation Estimates & Trend Analysis

  • 4.1. Topical Drugs CDMO Market, By Formulation: Segment Dashboard
  • 4.2. Topical Drugs CDMO Market, By Formulation: Movement Analysis
  • 4.3. Topical Drugs CDMO Market Estimates & Forecasts, By Formulation, 2021 - 2033 (USD Million)
  • 4.4. Semi-solid Formulations
    • 4.4.1. Semi-Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Creams
      • 4.4.2.1. Creams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Ointments
      • 4.4.3.1. Ointments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Gel
      • 4.4.4.1. Gel Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Liquid Formulations
    • 4.5.1. Liquid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Solid Formulations
    • 4.6.1. Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Transdermal Products
    • 4.7.1. Transdermal Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Topical Drugs CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Topical Drugs CDMO Market, Service: Segment Dashboard
  • 5.2. Topical Drugs CDMO Market, Service: Movement Analysis
  • 5.3. Topical Drugs CDMO Market Estimates & Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • 5.4. Contract Development
    • 5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Contract Manufacturing
    • 5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Topical Drugs CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Topical Drugs CDMO Market, By End Use: Segment Dashboard
  • 6.2. Topical Drugs CDMO Market, By End Use: Movement Analysis
  • 6.3. Topical Drugs CDMO Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Biopharmaceutical Companies
    • 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Topical Drugs CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2033
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Market Position Analysis, 2024 (Heat Map Analysis)
  • 8.3. Company Profiles
    • 8.3.1. Lubrizol Life Science
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Cambrex Corporation
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Contract Pharmaceuticals Limited
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Bora Pharmaceutical CDMO
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Ascendia Pharmaceuticals
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Pierre Fabre group
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Piramal Pharma Solutions
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. DPT Laboratories, LTD
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. MedPharm Ltd
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. PCI Pharma Services
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives

Chapter 9 Key Recommendations